Analysis of FDA Neuromodulation Device Recall in 2006-2015

Wei-ming WANG,Lu-ming LI,Hong-wei HAO,Chun-hua HU,Fang-jun LIU,Bo-zhi MA,Xiong-wei WEN
DOI: https://doi.org/10.15971/j.cnki.cmdi.2015.05.006
2015-01-01
Abstract:Objectives:Analyze FDA neuromodulation device recal information, especial y DBS and SCS. Method:For each recal event, the recal class and reason for recal were classiifed for analysis. Results:The total number of DBS and SCS recal events from October 20th, 2006 to January 12th, 2015 is 23, 21.9%of the total recal s by Medtronic neuromodulation division. The reasons for recal s are manufacturing, design, package and label, as wel as the auxiliary parts. The number of auxiliary parts recal events is 7, 30.4%of the total recal s by Medtronic neuromodulation division. The number of package and label recal events is 6, 26.1%of the total recal s by Medtronic neuromodulation division. The number of design recal events is 6, 26.1% of the total recal s by Medtronic neuromodulation division. The number of manufacturing recal events is 4, 17.4%of the total recal s by Medtronic neuromodulation division. DBS and SCS productions are rarely involved in FDA recal events in conclusion. The recal events for St. Jude Medical mainly focus on new rechargeable neuromodulation device and overheat is a mat er of concern, manufacturing is also slightly prominent. Recharging overheat and component failure is a mat er of concern. The recal events for implantable software are rarely observed, but correspondingly, non-implantable software needs to be considered. Conclusion:Usage of FDA medical device recal events should be strengthened in order to provide reference for review, supervision, related research and production.
What problem does this paper attempt to address?